British pharmaceutical company Neuro-Bio has received $3.2 million in financing from Los Angeles-based Kairos Ventures to continue developing a diagnostic tool for early detection of Alzheimer’s disease. This tool stems from a novel approach to Alzheimer’s pioneered in 2013 by Neuro-Bio’s founder and CEO, Susan Greenfield, and her team at Oxford University.
Resulting from 40 years of basic research, this approach focuses on a previously unidentified process that might be behind the continuing cycle of cell death that defines the neurodegenerative process. Neuro-Bio wants to see if drugs can stop the activation of these brain mechanisms, and if these processes can be tracked with blood biomarkers.
“We are delighted to have secured this Series A investment to support the continued growth of our company from start-up to small enterprise,” Greenfield said in a press release. “The investment from Kairos is the recognition of our fresh approach as well as the expertise of our team. This investment will increase the possibility of discovery of a novel disruptive treatment that is much needed to improve outcomes for patients with Alzheimer’s.”
The last few months have seen the demise of several anti-Alzheimer drug candidates. Neuro-Bio will now be able to open up a new direction in the search for an effective treatment.
“It is great to hear that a member of our network has secured significant funding,” said Mark Hooper of OBN, a nonprofit organization for innovative British life science institutions. “The fight against Alzheimer’s is a world concern, and this new initiative brings together a dynamic, innovative team of scientists from the UK with sound investment from the US to allow further development of a genuinely novel, disruptive approach for this life-shattering disease.”
Greenfield is a British scientist, writer, broadcaster and member of the House of Lords. Specializing in the physiology of the brain, Greenfield investigates the impact of modern technologies on the mind, on how the brain generates consciousness and novel approaches to neurodegenerative diseases like Alzheimer’s.